BEN-MAIMON CAROLE

President and CEO

BEN-MAIMON CAROLE has filed 2 SEC Form 4 filings (2 transaction rows) across 1 company, with disclosures dating back to 2026. 2 of those filings fall inside the rolling window. Most recent filing: Nov 12, 2026.

On the most recent filing, BEN-MAIMON CAROLE is listed as President and CEO at Larimar Therapeutics, Inc. Inside the rolling window, BEN-MAIMON CAROLE reported 1 open-market purchase totaling $50K in LRMR and no open-market sales.

Companies traded

Other insiders at LRMR

Insider Buying

$50K

reported purchases (SEC code P)

Insider Selling

$0

reported sales (SEC code S)

Companies

1

in the rolling window

Source
LRMRPurchase$50KNov 12SEC ↗
Showing 1–1 of 1
1 / 1

Frequently asked questions

How many SEC Form 4 filings has BEN-MAIMON CAROLE made?

BEN-MAIMON CAROLE has filed 2 SEC Form 4 filings (2 transaction rows) across 1 company since 2026.

Which companies does BEN-MAIMON CAROLE trade?

BEN-MAIMON CAROLE has filed SEC Form 4 disclosures for 1 company, including LRMR.

When was BEN-MAIMON CAROLE's most recent SEC Form 4 filing?

BEN-MAIMON CAROLE's most recent SEC Form 4 filing on Tracefour is dated Nov 12, 2026.

What is BEN-MAIMON CAROLE's job title?

On the most recent SEC Form 4 filings tracked by Tracefour, BEN-MAIMON CAROLE is listed as President and CEO.

What is BEN-MAIMON CAROLE's total buy and sell value in the current window?

Inside the rolling retention window, BEN-MAIMON CAROLE bought $50K and sold $0 based on SEC Form 4 filings.

What was BEN-MAIMON CAROLE's largest disclosed transaction?

The largest disclosed transaction in the current window is a purchase of 18,050 LRMR shares on 2026-11-11, worth $50K, per SEC Form 4 filings.